You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas: Oncology
Aro Biotherapeutics Names Cancer Biologist McMahon and Protein Structure and Design Expert Swanson to its Scientific Advisory Board
Login
Username:

Password:


Related Headlines

Formosa Pharmaceuticals submits Clinical Trial Application to European regulatory authorities for TSY-110

Kazia Therapeutics reports 100% clinical benefit rate in initial paxalisib breast cancer trial

DualityBio agrees global collaboration and licensing deal with Genentech

Cizzle Bio presents CIZ1B biomarker blood test for lung cancer at Next Generation Dx Summit

Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic GEA eligible for ZIIHERA

Daiichi Sankyo and AstraZeneca launch phase 3 trial of Datroway in high-risk bladder cancer

Inify Laboratories launches UK operations with first NHS agreement

Senhwa completes enrolment in Phase 1b expansion trial of CX-5461

McKesson to acquire Precision Medicine Group for approximately USD2.25bn

BreakBio set to enter clinic

Astellas doses first patient in Phase 3 study of ASP2138

Gilead expands Trodelvy role in first-line metastatic triple-negative breast cancer in Europe

GSK's Jemperli wins FDA priority review for advanced rectal cancer

Anbogen Therapeutics enters collaborative research agreement with University of Tokyo for ABT-301 evaluation across multiple tumour types

Leads Biolabs NDA for Opamtistomig accepted by China's CDE

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026